Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bandwidth Inc (BAND) vs Novavax Inc (NVAX) Price & Performance

Bandwidth IncTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Bandwidth Inc vs Novavax Inc — how do they compare? Bandwidth Inc trades at $77.48 (market cap $2.36B), while Novavax Inc trades at $8.46 (market cap $1.38B). The key difference: Bandwidth Inc is the larger of the two by market cap, and Bandwidth Inc is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.

BANDNVAX
Market Cap
$2.36B$1.38B
Sector
TechnologyHealth
52-Week High
$78.44$11.19
52-Week Low
$12.82$6.22
Enterprise Value
$2.74B$889.29M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bandwidth Inc

Bandwidth (BAND) trades at $73.81, down 2.21% today, with strong technical momentum indicated by bullish moving averages. The company reported Q1 2026 EPS of $0.38, beating expectations of $0.32, while revenue reached $753.82 million in 2025. Analyst sentiment is positive with 12 buy ratings and a consensus price target of $71.67. Recent news highlights AI-driven growth in cloud communications and a $275 million convertible notes offering to fuel expansion.

The outlook for BAND is cautiously optimistic, driven by AI infrastructure demand and cloud communications growth. Key risks include negative profit margins and high valuation multiples. Investment opportunity lies in execution of AI initiatives, but investors should monitor earnings sustainability and competitive pressures in the technology sector.

Novavax Inc

Novavax (NVAX) trades at $8.91, down 4.5% today, with a bearish technical signal despite recent earnings beats. The company shows mixed fundamentals with strong revenue of $1.12B in 2025 but negative equity of -$623.84M. Analyst consensus remains bullish with a $14.00 price target, though cash flow trends show ongoing operational losses. Recent news highlights shareholder dissent and market underperformance compared to peers.

The outlook is cautious; while valuation ratios like P/E of 3.14 appear attractive, persistent negative cash flow and high liabilities pose significant risks. Upside depends on sustainable profitability and execution amid competitive vaccine markets. Investors should weigh analyst optimism against fundamental weaknesses and volatility.

Returns comparison

Trailing returns across standard periods

About Bandwidth Inc

Bandwidth is a global communications software company. Its CPaaS platform allows enterprises to embed voice, messaging, and 911 emergency services directly into their software applications via robust APIs.

Read more on BAND

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX